The Vaccine Research Centre at NIAID has developed a scalable manufacturing process using non-affinity resins for the purification of Env trimers [60], and the Duke Consortia for HIV AIDS Vaccine Development also have a GMP facility for the manufacture of HIV antigens. This evidence concerns the gene ERVW-1 and AIDS.